607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan

Background

Melanoma brain metastasis has very poor prognosis, although recent treatment advances, including immune checkpoint inhibitors and targeted therapy, have improved the prognosis. We investigated the survival of Asian patients with melanoma brain metastasis and the effectiveness of radiotherapy and systemic therapies.

Methods

We retrospectively reviewed the survival rates of patients diagnosed with melanoma brain metastasis between January 2011 and December 2021 at the National Cancer Center Hospital in Tokyo, Japan. In addition, we identified factors associated with survival using Cox regression analysis.

Results

A total of 135 patients were included. The median overall survival after melanoma brain metastasis diagnosis was 7.8 months (95% confidence interval [CI] 6.1–9.6). The 6-month and 1-year survival rates were 60.7% and 34.8%, respectively. We identified the prognostic factors of melanoma brain metastasis, including non-acral primary location, low serum LDH levels, systemic therapy of single-agent immune check point inhibitors or targeted therapies, and radiotherapy of stereotactic irradiation. On the other hand, We found no significant difference in effectiveness between single-agent immune check point inhibitors, the combination of immune check point inhibitors, and targeted therapies.

Conclusions

We retrospectively investigated the survival of patients with melanoma brain metastasis at our facility. The survival of Asian patients with melanoma brain metastasis is relatively poor compared to that of Caucasian patients. Immune check point inhibitor, targeted therapy, and radiotherapy of stereotactic irradiation were associated with improved survival; however, we found no significant superiority of the combination of immune check point inhibitors over single-agent immune check point inhibitor or targeted therapy in terms of effectiveness. Further investigations using larger cohorts, multicenter analyses, and prospective studies are necessary to assess the effectiveness of systemic therapy in Asian patients with melanoma brain metastasis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Dermatologic oncology department in National Cancer Center Hospital.

Funding

Has not received any funding.

Disclosure

N. Yamazaki: Financial Interests, Personal, Advisory Board: Ono, Chugai; Financial Interests, Personal, Invited Speaker: Ono, Bristol Myers Squibb, Novartis, MSD, Maruho; Financial Interests, Institutional, Research Grant: Ono, Bristol Myers Squibb, Novartis, Amgen. K. Namikawa: Financial Interests, Personal, Advisory Board: MSD, Novartis; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, Novartis, MSD, Ono. All other authors have declared no conflicts of interest.